首页> 外文期刊>Clinical microbiology and infection: European Society of Clinical Microbiology and Infectious Diseases >Knowing prior methicillin-resistant Staphylococcus aureus (MRSA) infection or colonization status increases the empirical use of glycopeptides in MRSA bacteraemia and may decrease mortality
【24h】

Knowing prior methicillin-resistant Staphylococcus aureus (MRSA) infection or colonization status increases the empirical use of glycopeptides in MRSA bacteraemia and may decrease mortality

机译:知道以前耐甲氧西林的金黄色葡萄球菌(MRSA)感染或定殖状态会增加糖肽在MRSA菌血症中的经验使用,并可能降低死亡率

获取原文
获取原文并翻译 | 示例
           

摘要

To compare the management and outcome of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia in patients known to be MRSA-colonized/infected (C-patients) with the management and outcome in those not known to be colonized/infected (NC-patients), we conducted a 10-year retrospective review of MRSA bacteraemia in an adult tertiary hospital. Clinical data were obtained by chart review, and mortality data from linked databases. Prior MRSA colonization/infection status was available to treating clinicians at the time of the bacteraemia as a 'Micro-Alert' tag on the patient's labels, in medical charts, and in electronic information systems. C-patients accounted for 35.4% of all MRSA bacteraemia episodes. C-patients were more likely to be indigenous, to be diabetic, or to have a history of previous S. aureus infection. Markers of illness severity (Simplified Acute Physiology Score (SAPS)-II, need for admission to the intensive-care unit, length of stay, and metastatic seeding) were similar in both groups. Empirical therapy included a glycopeptide in 49.3% of C-patients vs. 18.9% of NC-patients (p <0.01), and contained an antibiotic to which the MRSA isolate tested susceptible in vitro in 56.7% of C-patients vs. 45.1% of NC-patients (p 0.13). All-cause 7-day and 30-day mortality were 7.5% vs. 18.9% (p 0.04), and 22.4% vs. 31.1% (p 0.20), in the C-patient and NC-patient groups, respectively. Knowing MRSA colonization status was significantly associated with lower 30-day mortality in Cox regression analysis (p <0.01). These data suggest that mortality from MRSA bacteraemia is lower in C-patients, which may reflect the earlier use of glycopeptides. The low use of empirical glycopeptides in septic patients known to be previously MRSA-colonized/infected may represent a missed opportunity for infection control to positively impact on clinical management.
机译:比较已知甲氧西林耐药/金黄色葡萄球菌(MRSA)菌血症(C型患者)的管理和结果与未知克隆/传染性(NC患者)的管理和结果,我们在一家成人三级医院对MRSA菌血症进行了10年的回顾性研究。通过图表审查获得临床数据,并从链接的数据库获得死亡率数据。菌血症发生时,临床医生可将先前的MRSA定植/感染状态作为患者标签,病历表和电子信息系统中的“微警报”标签。 C病人占所有MRSA菌血症发作的35.4%。 C型患者更有可能是本地人,糖尿病患者或曾有过金黄色葡萄球菌感染的病史。两组患者的疾病严重程度指标(简化的急性生理评分(SAPS)-II,需要进入重症监护病房,住院时间和转移灶)相似。经验疗法包括在C病人中占49.3%的糖肽,而在NC病人中占18.9%(p <0.01),并且在56.7%的C病人中对抗生素进行了MRSA分离物测试,对抗生素的敏感性为45.1%。的NC患者(p 0.13)。 C组和NC组的全天7天和30天死亡率分别为7.5%对18.9%(p 0.04)和22.4%对31.1%(p 0.20)。在Cox回归分析中,了解MRSA定殖状态与30天较低的死亡率显着相关(p <0.01)。这些数据表明,C患者的MRSA菌血症死亡率较低,这可能反映了糖肽的早期使用。在已知先前已被MRSA克隆/感染的脓毒症患者中,经验性糖肽的使用率低可能代表错过了控制感染对临床管理产生积极影响的机会。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号